NASDAQ:AGEN - Agenus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agenus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.83 -0.05 (-1.29 %) (As of 12/13/2019 07:49 AM ET) Add Compare Today's Range$3.81Now: $3.83▼$3.9750-Day Range$2.41MA: $3.58▼$4.4152-Week Range$1.95Now: $3.83▼$4.57Volume543,495 shsAverage Volume1.49 million shsMarket Capitalization$526.09 millionP/E RatioN/ADividend YieldN/ABeta2.06 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN Previous Symbol CUSIP00847G70 CIK1098972 Webhttp://agenusbio.com/ Phone781-674-4400Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.78 million Price / Sales14.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.45) per share Price / Book-2.64Profitability EPS (Most Recent Fiscal Year)($1.44) Net Income$-159,690,000.00 Net Margins-107.15% Return on EquityN/A Return on Assets-67.84%Miscellaneous Employees294 Outstanding Shares137,360,000Market Cap$526.09 million Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive AGEN News and Ratings via Email Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AGEN Rates by TradingView Agenus (NASDAQ:AGEN) Frequently Asked Questions What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." How were Agenus' earnings last quarter? Agenus Inc (NASDAQ:AGEN) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.05. The biotechnology company had revenue of $19.94 million for the quarter, compared to the consensus estimate of $15.60 million. View Agenus' Earnings History. When is Agenus' next earnings date? Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Agenus. What price target have analysts set for AGEN? 1 equities research analysts have issued twelve-month price targets for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 56.7% from the stock's current price. View Analyst Price Targets for Agenus. What is the consensus analysts' recommendation for Agenus? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus. Has Agenus been receiving favorable news coverage? News coverage about AGEN stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Agenus. Who are some of Agenus' key competitors? Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), Merrimack Pharmaceuticals (MACK), REDHILL BIOPHAR/S (RDHL), Opko Health (OPK), Gilead Sciences (gild), Energy Transfer LP Unit (ET), Synergy Pharmaceuticals (SGYP), Novavax (NVAX) and Cara Therapeutics (CARA). Who are Agenus' key executives? Agenus' management team includes the folowing people: Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)Dr. Jennifer Buell, Chief Operating OfficerDr. Alexander R. Duncan, CTO & Head of Research (Age 57)Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53) Who are Agenus' major shareholders? Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.75%), Millennium Management LLC (0.55%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%), California State Teachers Retirement System (0.12%) and Barclays PLC (0.05%). View Institutional Ownership Trends for Agenus. Which institutional investors are selling Agenus stock? AGEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Barclays PLC, Alberta Investment Management Corp, Metropolitan Life Insurance Co NY and Alps Advisors Inc.. View Insider Buying and Selling for Agenus. Which institutional investors are buying Agenus stock? AGEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Millennium Management LLC, California Public Employees Retirement System, Commonwealth Equity Services LLC, Virtu Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Agenus. How do I buy shares of Agenus? Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $3.83. How big of a company is Agenus? Agenus has a market capitalization of $526.09 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus. What is Agenus' official website? The official website for Agenus is http://agenusbio.com/. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected] MarketBeat Community Rating for Agenus (NASDAQ AGEN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 404 (Vote Outperform)Underperform Votes: 312 (Vote Underperform)Total Votes: 716MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: What are high-yield dividend stocks?